CagriSema
Novo Nordisk's investigational combination of cagrilintide (an amylin analog) and semaglutide in one weekly injection.
CagriSema pairs two appetite hormones in one pen: semaglutide, the GLP-1 agonist behind Wegovy, and cagrilintide, a long-acting analog of amylin — the hormone co-released with insulin that slows stomach emptying and promotes fullness through a separate brain pathway. Attacking appetite from two directions is the same logic that made tirzepatide's dual action famous.
Phase 3 results reported averages in the low-to-mid 20s percentagewise, positioning CagriSema as Novo's answer to tirzepatide and retatrutide. It is not yet FDA-approved, so it matters to patients today mainly as a signal: the brand you start on now is unlikely to be the strongest option available five years from now, and switching paths under a doctor's guidance is normal in this field.
This glossary entry is general information, not medical advice, and is written to be consistent with FDA prescribing information and primary trial publications as of its last review. Always consult a licensed healthcare provider for personal medical decisions.
Questions about CagriSema? Ask a doctor free.
A licensed doctor can apply this to your health history in a free telehealth consultation — booking takes about two minutes, with programs from $149/month. You're only charged after approval.
Book an Appointment